In This Article:
Singapore-based biotechnology company CytoMed Therapeutics has signed a five-year business and research collaboration agreement (BRCA) with SunAct Cancer Institute for a Phase II clinical trial in India.
The trial will investigate the efficacy, safety, tolerability and potency of CytoMed's allogeneic gamma delta T cells in treating various cancers, including solid tumours.
Both entities will jointly sponsor the clinical trial, which will be led by SunAct founder, medical oncologist and immunotherapy specialist Dr Vijay Patil.
Dr Patil said: “This collaboration with CytoMed will provide an alternative treatment for a wide range of solid cancers at a reduced cost to an increasing host of the population of India suffering from the effects of cancer.
“We aim to provide much-needed access to and treatment for cancer at an affordable cost and to contribute to an increasing and much-needed global data pool in our quest for a solution to fight cancer.”
Under the BRCA, CytoMed will provide scientific and technical support for the clinical trial, as well as manufacture the allogeneic gamma delta T cells.
SunAct and Dr Patil will offer their local expertise, knowledge of Indian regulations, and access to healthcare resources and patient populations.
CytoMed chairman Peter Choo said: “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers at affordable cost.
“We are excited to work with Dr Vijay Patil in our goal to accelerate the therapeutic application of CytoMed’s patented allogeneic gamma delta T-Cells (Patent Number: MY-200528-A; ZL 2018 8 0023646.8; US 11,629,333 B2) in an increasing population of cancer patients in India and around the world.”
Founded in 2018, CytoMed works to create novel cell-based cancer immunotherapies using gamma delta T cell and gamma delta Natural Killer T cell technologies.
"CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.